3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
13
Tumor-Agnostic
7
Lymphoid
3
Thoracic
2
Genitourinary
2
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Classical hematology
1
CNS
1
Conditions
Endometrial Neoplasms
10
Ovarian Neoplasms
7
Breast Neoplasms
4
Neoplasms
2
Fallopian Tube Neoplasms
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Low Grade Serous Ovarian Carcinoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Endometrioid Adenocarcinoma
1
ER+ HER2- Advanced Breast Cancer
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Breast Diseases
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
22
Paclitaxel
14
Cyclophosphamide
13
Carboplatin
11
Specimen Handling
10
Magnetic Resonance Spectroscopy
10
Biopsy
9
fludarabine
8
Nivolumab
7
Leucovorin
7
Gemcitabine
7
Fluorouracil
7
Doxorubicin
7
aldesleukin
6
Oxaliplatin
6
liposomal doxorubicin
5
Topotecan
5
Taxes
5
Irinotecan
5
Interleukin-2
5
Cisplatin
5
olaparib
4
atezolizumab
4
Hyperthermic Intraperitoneal Chemotherapy
4
Drug Therapy
4
seribantumab
3
fludarabine phosphate
3
durvalumab
3
dostarlimab
3
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
abemaciclib
×
Gynecologic
×
Clear all
NCT05735080
2026-04-01
INX-315-01
Incyclix Bio
Phase 1/2
Recruiting
150 enrolled